BKM120
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Prostate Cancer
Conditions
High Risk Prostate Cancer
Trial Timeline
Apr 23, 2013 → Feb 5, 2015
NCT ID
NCT01695473About BKM120
BKM120 is a phase 2 stage product being developed by Novartis for High Risk Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01695473. Target conditions include High Risk Prostate Cancer.
What happened to similar drugs?
3 of 20 similar drugs in High Risk Prostate Cancer were approved
Approved (3) Terminated (6) Active (12)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01613677 | Phase 2 | Withdrawn |
| NCT02220855 | Phase 2 | Completed |
| NCT01550380 | Phase 2 | Withdrawn |
| NCT01695473 | Phase 2 | Terminated |
| NCT02128724 | Phase 1 | Completed |
| NCT01833169 | Phase 2 | Completed |
| NCT01513356 | Phase 1 | Completed |
| NCT01626209 | Phase 1 | Completed |
| NCT01396499 | Phase 1 | Completed |
| NCT01629615 | Phase 2 | Completed |
| NCT01501604 | Phase 2 | Withdrawn |
| NCT01727128 | Phase 1 | Completed |
| NCT01339052 | Phase 2 | Completed |
| NCT01385293 | Phase 2 | Terminated |
| NCT01297491 | Phase 2 | Completed |
| NCT01289041 | Phase 2 | Completed |
| NCT01283503 | Phase 1 | Completed |
| NCT01068483 | Phase 1 | Completed |
Competing Products
20 competing products in High Risk Prostate Cancer